

Mereo BioPharma Group plc
Fourth Floor
One Cavendish Place
London W1G 0QF
United Kingdom

March 18, 2020

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Mereo BioPharma Group plc
Registration Statement on Form F-1
File No. 333-236497

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-236497) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on March 19, 2020 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Mayer Brown LLP, by calling David S. Bakst at (212) 506-2551. The Company hereby authorizes Mr. Bakst to orally modify or withdraw this request for acceleration.

Very truly yours,

MEREO BIOPHARMA GROUP PLC

By: /s/ Denise Scots-Knight

Name: Denise Scots-Knight

Title: Chief Executive Officer

Cc: David S. Bakst
Mayer Brown LLP

Richard Jones
Charles Sermon
Mereo BioPharma Group plc